PolyPid to Present at the Barclays Global Healthcare Conference

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced its participation in the Barclays Global Healthcare Conference from March 15-17, 2022. The company will present on March 16 at 9:00 AM Eastern Time. PolyPid specializes in Phase 3 biopharmaceutical developments, focusing on targeted, locally administered, prolonged-release therapeutics via its proprietary PLEX technology. Its lead product candidate, D-PLEX100, is undergoing clinical trials aimed at preventing surgical site infections.

Investors interested in the conference can contact Barclays representatives for meetings.

PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 15-17, 2022.

Barclays Global Investor Conference:

Presentation Date:	Wednesday, March 16, 2022
Presentation Time:	9:00 AM Eastern Time
Webcast:	https://barclays.webcasts.com/starthere.jsp?ei=1533028&tp_key=1d6b22fa07&tp_special=8

Following the live presentation, a replay of the presentation will be available under the Investor section of PolyPid’s website at https://investors.polypid.com/events-and-presentations/events and archived for 30 days thereafter. Investors interested in meeting with PolyPid during the conference should contact their Barclays representative.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD), is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of abdominal and sternal surgical site infections (SSIs).
For additional Company information, please visit polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 
PolyPid, Ltd. 
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media Contact:
Nechama Feuerstein
551-444-0784
Nechama.Feuerstein@finnpartners.com

FAQ

When is PolyPid's presentation at the Barclays Global Healthcare Conference?

PolyPid will present on March 16, 2022, at 9:00 AM Eastern Time.

What is PolyPid's lead product candidate?

PolyPid's lead product candidate is D-PLEX100, which is in Phase 3 clinical trials for preventing surgical site infections.

Where can I watch the PolyPid presentation?

The presentation can be viewed via webcast at Barclays' website, with a replay available on PolyPid's investor section afterward.

What technology does PolyPid use for its therapeutics?

PolyPid utilizes its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology for controlled, extended-release therapeutics.

What is the purpose of the Barclays Global Healthcare Conference?

The conference is designed for health sector companies to present their latest developments to investors and stakeholders.